PAR

5.00%

19.0¢ paradigm biopharmaceuticals limited..

Trial PAR008 is on ANZCTR, page-66

First 66 Last

Share
Profile

Follow
Dungiven

1,748 Posts.

1895

12/11/21

15:02

Post #: 57533145
Share

Originally posted by Zenox: ↑

There are a lot of issues with LOR which make it difficult to ascertain whether it will be considered favourably by the FDA, so I wouldn't consider it competition just yet. Here are some of the concerns the FDA are likely to have:

1. It was a post-hoc analysis from a failed study.

2. Background analgesia makes it difficult to determine the extent of the effect due to LOR.

3. Dropouts were excluded from analysis. Dropouts are most likely non-responders. FDA will perform sensitivity analysis and will treat dropouts as non-responders, which will negatively impact on the overall results.

4. The type of analysis performed was responder analysis, which you have to be cautious of when interpreting these results. For responder analysis you need to be able to identify who will respond to your treatment beforehand, which they are unable to just yet.

For the responder analysis, responders were compared groupwise between the LOR and PBO groups and logistic regression was performed on the full analysis set with non-responder imputation. These are not stringent forms of analyses, particularly imputation.

Article: Comparisons against baseline within randomised groups are often used and can be highly misleading
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286439/

5. The dosage results are inconsistent and not dose dependent. Why does 0.07 LOR dose 'work', but not 0.15? The overall number of participants in this group were small ~ 60-70 participants in each group.

6. Type 1 error control was not employed in the post hoc response analysis, so you can't trust the p values.

7. There are no objective measures supporting their findings i.e. no MRI scans.

The best case scenario for LOR is it will be considered as part of the treatment algorithm that will also include iPPS, but they still have a mountain to climb.

Expand

What a post!

Just on that failed Phase 2a trial for Lorecivivint, the primary endpoint was pain score and no dose showed statistical significance against placebo. The researchers, as is their wont, looked for silver linings - but Dr David Felson was not having any of it...

Bang!

https://www.medpagetoday.com/rheumatology/arthritis/86677

PAR Price at posting: $2.25 Sentiment: Buy Disclosure: Held
14 Upvote

4 Great analysis

Reply

Top Stories

The winners & losers on market if negative gearing were gone

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

There are more pages in this discussion • 2 more messages in this thread...

First 66 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change -0.010(5.00%)		Mkt cap ! $66.54M

Open	High	Low	Value	Volume
20.0¢	21.0¢	19.0¢	$203.4K	1.019M

Buyers (Bids)

No.	Vol.	Price($)
14	387930	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
20.5¢	65468	2

View Market Depth

No.	Vol.	Price($)
14	387930	0.190
3	57000	0.185
10	205428	0.180
6	140904	0.175
8	615605	0.170

Price($)	Vol.	No.
0.205	65468	2
0.210	28079	4
0.215	30000	1
0.220	27066	4
0.225	21604	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

PAR (ASX) Chart

Trial PAR008 is on ANZCTR, page-66

The winners & losers on market if negative gearing were gone

Zeta Resources seeks to resolve the Panoramic takeover story

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Trial PAR008 is on ANZCTR, page-66

Top Stories

The winners & losers on market if negative gearing were gone

Zeta Resources seeks to resolve the Panoramic takeover story

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News